Epiminder (ASX:EPI) has received FDA 510(k) clearance to expand the indicated age range for its Minder® System to patients aged 12 years and older with drug-resistant epilepsy, extending access beyond its original clearance for patients aged 18-75 years.
announcements.asx.com.au/asxpdf/2026103…
• Investor, media, digital relations agency
• Trusted by Australia's top companies
• Empowering the extraordinary

